CCL2 and rheumatoid arthritis: So far, conducted clinical trials failed to demonstrate an effect of CCR2/CCL2 blocking antibodies in RA (23, 24), which may be due to numerous reasons (62); however, the research duration was short and focused on inflammation dampening outcomes, and the potential beneficial effects on bone were not evaluated.